GlassScriptPhysician profile
Joann H Lamb
NPI 1083620116
$12,915.37
in general payments reported to CMS, 2019-2025
50 companies · $1,963 in 2025
The $1,963 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,549 · 2020: $944 · 2021: $938 · 2022: $2,252 · 2023: $2,048 · 2024: $2,220 · 2025: $1,963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,222 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,222.05 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,068.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,258.13 | 2019-2025 | Farxiga, Breztri |
| Pfizer INC. | $1,177.59 | 2019-2025 | |
| Abbvie INC. | $1,123.26 | 2019-2025 | |
| Lilly USA, LLC | $865.54 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $716.67 | 2019-2025 | Repatha, Evenity, Prolia |
| Glaxosmithkline, LLC. | $448.20 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $434.85 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $347.73 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $325.42 | 2019-2025 | Jardiance, Ofev |
| Merck Sharp & Dohme LLC | $311.75 | 2019-2025 | Capvaxive, Verquvo, Belsomra |
| Novartis Pharmaceuticals Corporation | $297.79 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $222.32 | 2019-2025 | Zoryve, Seglentis, Livalo |
| E.R. Squibb & Sons, L.L.C. | $216.32 | 2019-2025 | Camzyos, Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $191.99 | 2019-2025 | Trintellix, Glassia |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joann Lamb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.